Sildenafil Tablet, Film Coated
Product Images NDC 50090-5236

8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Sildenafil, showing its molecular framework including ring systems and functional groups consistent with the active ingredient Sildenafil.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A chart showing fold change and 90% confidence intervals for pharmacokinetic variables (AUC and Cmax) of Sildenafil when coadministered with various interacting drugs. The chart includes drugs like Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, with corresponding dose adjustment recommendations, mostly 'No dose adjustment' except for Ritonavir where coadministration is not recommended.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart showing fold change and 90% confidence intervals for various interacting drugs with sildenafil, comparing parameters such as AUC, Cmax, INR, and bleeding time relative to the interacting drug alone. The chart includes recommendations on dose adjustments, mostly indicating no dose adjustment except coadministration notes for bosentan and ritonavir, and contraindication for saquinavir.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A scatter plot graph depicting changes from baseline in meters over a 12-week study. The chart compares placebo and three Sildenafil doses (20 mg, 40 mg, and 80 mg TID) at weeks 4, 8, and 12, including error bars representing variability. The x-axis shows study weeks; the y-axis shows change from baseline in meters.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A forest plot illustrating the placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg taken three times daily (TID). The chart compares groups based on baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary artery pressure, and pulmonary vascular resistance index, with sample sizes for placebo and Sildenafil groups noted for each category.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph depicting the percentage of subjects without a clinically worsening event over days from randomization, comparing two groups: Placebo (solid line) and Sildenafil (dashed line). The y-axis shows the percentage from 0 to 100, and the x-axis shows days from 0 to 112. The Sildenafil group maintains a higher percentage without worsening events throughout the period compared to the Placebo group.*
FDA Label Image

Camber1 (Camber1)

FDA Label Image

Label Image (Lbl500905236)

Label Image (Lbl500905236)
Sildenafil 20 mg film-coated tablets packaging label from A-S Medication Solutions. The label displays the dosage strength of 20 mg, product and lot numbers, storage instructions to keep between 68 and 77 degrees Fahrenheit, and a count of 30 tablets. The label also includes directions to see the package insert for dosing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.